Rehabilitation, Education, and SElf-management for Adolescents After Mild Traumatic Brain Injury

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-18
SponsorMolly Cairncross

About this trial

Concussion or mild traumatic brain injury (mTBI) is a major public health concern. Most adolescents will recover from mTBI without complication; however, a sizeable minority experience symptoms that last more than one most post-injury (i.e., persisting symptoms after concussion). Few evidence-based treatments exist for adolescents with persisting symptoms after concussion. Mindfulness-based interventions (MBIs) are effective for treating a wide range of mental and physical health conditions that overlap with post-concussion symptoms. Participants will participate in an 8-week smartphone app-based MBI or a health education program as a control. The study will determine the practicality of doing a larger study to evaluate the effectiveness of the MBI by assessing participants' level of interest, view of intervention helpfulness, and their completion of all the components of the study.

Eligibility criteria

Qualifiers

Age 12-18

Structured interview confirming a concussion/mTBI or suspected concussion/mTBI diagnosis according to the American Congress of Rehabilitation Medicine definition

Concussion/mTBI occurred 1-12 months prior to randomization

Persisting symptoms after concussion as demonstrated by a score >75th percentile on the Health and Behaviour Inventory compared to orthopedic injury normative group

Disqualifiers

Parent- or self-reported psychiatric hospitalization in past year or prior diagnosis of a psychiatric disorders or psychiatric symptoms that may be contraindicated for mindfulness-based interventions (e.g., psychosis)

Participation in a clinical trial using the Dawn intervention app in acute concussion (e.g., <2 weeks post-injury).

Trial design

Treatments tested in this trial

  • Mindfulness-based intervention
  • Health Education

Treatment groups

72 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Molly Cairncross

Lead sponsor

Simon Fraser University

Sponsor institution